Indoco Remedies receives USFDA’s approval for Lacosamide Tablets

22 Mar 2022 Evaluate

Indoco Remedies has received final approval from the United States Food & Drug Administration (USFDA) for Lacosamide Tablets USP 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat Tablets of UCB, Inc. Lacosamide Tablets are indicated for the prevention and control of seizures. It is an anticonvulsant/antiepileptic drug. According to IQVIA sales data for the period ending January 2022, Vimpat Tablets market achieved annual sales of approximately $1.7 billion.

The ANDA approval for Lacosamide Tablets on the day of patent expiry, reverberates the company’s enduring commitment to make quality and affordable generic medicines available to more patients in the United States. Its first shipment of Lacosamide Tablets has already reached US.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

231.20 -3.60 (-1.53%)
01-Jan-2026 13:50 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1717.30
Dr. Reddys Lab 1250.75
Cipla 1499.50
Zydus Lifesciences 913.35
Lupin 2099.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×